OSAKA - Japanese pharmaceutical firm Shionogi & Co. said Wednesday its oral COVID-19 drug currently under development has been confirmed in preclinical testing as effective against the Omicron subvariant BA.2.75 that has been detected in Japan.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
